Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics.
The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.
Today, ExpreS2ion Biotechnologies’ management presented the financial results for Q3 2026 and gave further insights into recent pipeline developments, with focus on the breast cancer candidate ES2B-C001 and the Phase I primary readout expected in Q1 2027. The session was followed by a Q&A.
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Wirtek offentliggjorde i går delårsrapporten for tredje kvartal med en omsætning på DKK 15,2 mio. (Q3 2025: DKK 16,6 mio.) og EBITDA på DKK 0,5 mio. (Q3 2025: DKK 0,7 mio.). Lundbeck leverede tirsdag regnskab for de første ni måneder af 2026 og opjusterede samtidig helårsforventningerne for anden gang i år. ExpreS2ion Biotech er her til morgen ude med sit Q3-regnskab, hvor de kliniske tal i vid udstrækning gentager selskabsmeddelelsen fra 23. oktober.
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Kl. 10:00 præsenterer ExpreS2ion Biotech CEO Bent U. Frandsen og CFO Keith Alexander delårsrapporten for Q3 2026. Kl. 13:00 præsenterer Lundbeck Jens Høyer, Vice President & Head of Investor Relations, delårsrapporten for Q3 2026. Kl. 14:30 præsenterer Wirtek CEO Michael Aaen og CFO Mads Greiffenberg delårsrapporten for Q3 2026.
I relation til DADC, meldte NASA i fredags en opdateret Artemis-plan på et pressemøde med den nye NASA Chef, hvor Artemis III omlægges til en bemandet demonstrationsmission i lav jordkredsløb i 2027. ExpreS2ion offentliggjorde fredag, at alle 19 patienter i fase I-studiet med kræftvaccinekandidaten ES2B-C001 nu er inkluderet og i behandling.
ExpreS2ion today provided an update on the Phase I trial of ES2B-C001, confirming that all 19 planned patients have been enrolled and started treatment. The primary readout is consequently guided for publication in Q1 2027 rather than end-2026, with database lock in February
ExpreS2ion announced late yesterday that it has obtained a guarantee undertaking of approximately SEK 19.3m, equal to around 60% of the maximum proceeds from the ongoing TO 13 warrant programme, and CEO Bent U. Frandsen states that the undertakings secure the capital to advance ES2B-C001 through its primary Phase I read-out.
